# A Study of Docetaxel for Injection (Albumin Bound) in Patients With Advanced Pancreatic Cancer

Source: https://onco.cc/trials/nct06492941/  
OnCo record `nct06492941` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in pancreatic cancer, run by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., not yet recruiting.

## Summary

A Study of Docetaxel for Injection (Albumin Bound) in Patients With Advanced Pancreatic Cancer is a phase 3, randomised interventional study registered as NCT06492941 by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., with a registry enrolment figure of 142 participants, started 2024-08-12 and due to reach its primary completion in 2026-04-14. Interventions recorded: Docetaxel for Injection (Albumin bound); Placebo; Best supportive care. Conditions listed: Advanced Pancreatic Cancer. Primary outcome: OS. Pancreatic eligibility wording from the registry: "Histologically or cytologically confirmed diagnosis of pancreatic cancer (including adenosquamous carcinoma)". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06492941
- Phase: 3
- Setting: A Randomized, Double-blind, Multicenter Phase III Clinical Study of Docetaxel for Injection (Albumin Bound) Combined With Best Supportive Care Versus Placebo Plus Best Supportive Care in Advanced Pancreatic Cancer
- Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Enrolled: 142

## Sources

- ClinicalTrials.gov NCT06492941: https://clinicaltrials.gov/study/NCT06492941

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06492941.json